A Delaware Chancery Court judge has allowed an investor in a Silicon Valley biosciences firm to proceed with a derivative lawsuit claiming that the company’s board had delayed publicly announcing the issuance of a key patent in order to “spring-load” their own stock options.
Vice Chancellor Kathaleen S. McCormick ruled Thursday that plaintiff Thomas S. Howland Jr. and his Fox Rothschild attorneys had supported claims for breaches of fiduciary duty and unjust enrichment against the officers and directors of Anixa Biosciences Inc. stemming from the September 2017 transaction.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]